摘要
目的 探讨EGFR突变肺腺癌和大疱性类天疱疮之间的关系及阿美替尼的疗效.方法 收集1 例肺腺癌伴大疱性类天疱疮患者的临床资料,经组织病理学及二代测序基因检测明确病理及分子诊断,并检索相关文献对疾病的发病机制和治疗进行总结分析.结果 结合影像及组织病理学明确诊断为转移性肺腺癌伴大疱性类天疱疮,二代测序基因检测结果为EGFR 19 外显子缺失敏感突变.给予阿美替尼治疗,定期复查胸部CT,抗肿瘤治疗疗效评价为部分缓解,并且皮肤病变持续好转,患者无明显不良反应.结论 EGFR突变转移性肺腺癌合并大疱性类天疱疮患者可选择靶向药物治疗,阿美替尼有较好疗效及安全性.
Abstract
Objective To explore the relationship between lung adenocarcinoma with EGFR sensitizing mutation and bullous pemphigoid,as well as the benefit of almonertinib.Methods Clinical data from a case of lung adenocarcinoma complicated with bullous pemphigoid was collected.Pathological and molecular diagnosis was confirmed through his-topathological examination and next-generation sequencing genetic testing.Literature review was then conducted to sum-marize and analyze the disease's pathogenesis and treatment options.Results The diagnosis of metastatic lung adeno-carcinoma with bullous pemphigoid was established through imaging and histopathology examination.Next-generation sequencing revealed a sensitizing mutation of exon 19 deletion in the EGFR gene.The patient was treated with almoner-tinib with regular chest CT evaluations.The anti-tumor treatment efficacy was assessed to be partial response,and the skin lesions continued to improve with no significant adverse reactions.Conclusion Targeted therapies can be consid-ered in patients with EGFR-mutant metastatic lung adenocarcinoma complicated by bullous pemphigoid and almonertinib demonstrates good efficacy and safety.
NETL
NSTL
万方数据